Abstract:Purpose of review: Gastroparesis is a chronic disorder characterized by a constellation of foregut symptoms, including postprandial nausea, vomiting, distension, epigastric pain, and regurgitation in the absence of gastric outlet obstruction. Despite considerable research over the past decades, there remains to be only nominal understanding of disease classification, diagnostic criteria, pathogenesis, and preferred therapy. Recent findings: We critically reassess current approaches for disease identification and stratification, theories of causation, and treatment for gastroparesis. Gastric scintigraphy, long considered a diagnostic standard, has been re-evaluated in light of evidence showing low sensitivity, whereas newer testing modalities are incompletely validated. Present concepts of pathogenesis do not provide a unified model linking biological impairments with clinical manifestations, whereas available pharmacological and anatomical treatments lack explicit selection criteria or evidence for sustained effectiveness. We propose a disease model that embodies the re-programming of distributed neuro-immune interactions in the gastric wall by inflammatory perturbants. These interactions, combined with effects on the foregut hormonal milieu and brain-gut axis, are postulated to generate the syndromic attributes characteristically linked with gastroparesis. Research linking models of immunopathogenesis with diagnostic and therapeutic paradigms will lead to reclassifications of gastroparesis that guide future trials and technological developments. Key points: • The term gastroparesis embodies a heterogenous array of symptoms and clinical findings based on a complex assimilation of afferent and efferent mechanisms, gastrointestinal locations, and pathologies. • There currently exists no single test or group of tests with sufficient capacity to be termed a definitional standard for gastroparesis. • Present research regarding pathogenesis suggests the importance of immune regulation of intrinsic oscillatory activity involving myenteric nerves, interstitial cells of Cajal, and smooth muscle cells. • Prokinetic pharmaceuticals remain the mainstay of management, although novel treatments are being studied that are directed to alternative muscle/nerve receptors, electromodulation of the brain-gut axis, and anatomical (endoscopic, surgical) interventions.

Influence of extrusion and digestion on the nanostructure of high-amylose maize starch.

Su1632 - Spinal Cord Stimulation Improves Glucagon-Induced Impairment in Gastric Motility and Slow Waves Via Vagal Mechanisms in Dogs

Clinicoepidemiological Profile and Outcome of Children With Wilms Tumor in a Developing Country

Transcriptomic signatures reveal immune dysregulation in human diabetic and idiopathic gastroparesis

Immunohistochemical characterization of interstitial cells and their spatial relationship to motor neurons within the mouse esophagus

Downregulation of FAK-related non-kinase mediates the migratory phenotype of human fibrotic lung fibroblasts.

Enteric GFAP expression and phosphorylation in Parkinson's disease

Transport and Innovation : Unleashing the Potential Transport and Innovation : Un / Leashing the Potential

GPCRs expressed by cancer‐associated fibroblasts are potential therapeutic targets in pancreatic cancer

Glucagon-like peptide 1 receptor (GLP-1R) expression by nerve fibres in inflammatory bowel disease and functional effects in cultured neurons

[Variability analysis of S2 gene of SARS-CoV].

Imaging in Gastroparesis: Exploring Innovative Diagnostic Approaches, Symptoms, and Treatment

Identification of CGNL1 as a diagnostic marker in fibroblasts of diabetic foot ulcers: Insights from single cell RNA sequencing and bulk sequencing data

Involvement of oxidative stress-AMPK-Cx43-NLRP3 pathway in extracellular matrix remodeling of gastric smooth muscle cells in rats with diabetic gastroparesis

Reconsideration of the Gastroparetic Syndrome

Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging

1394-P: Peri-Islet Glial-Cell Expansion Occurs in Response to High-Fat Diet-Induced Obesity and Hyperglycemia

Abstract 719: PFKFB3 Mediated Glycolysis in Vascular Smooth Muscle Cells is Essential for Arterial Neointima Formation

Gastroparesis and Functional Dyspepsia: A Blurring Distinction of Pathophysiology and Treatment

Dysphagia associated with esophageal wall thickening in patients with nonspecific high‐resolution manometry findings: Understanding motility beyond the Chicago classification version 4.0

Ghrelin Bridges DMV Neuropathology and GI Dysfunction in the Early Stages of Parkinson's Disease